Dopamine
This supercharged pipeline promises more effective therapies will be available sooner .
RESEARCH
THE MICHAEL J . FOX FOUNDATION 2023 YEAR IN REVIEW misfolded alpha-synuclein enroll only those participants who have this dysfunctional biology in their brain and body cells ( including those already diagnosed with Parkinson ’ s as well as those not yet diagnosed ). This has never before been possible in Parkinson ’ s research , and it maximizes the opportunity to definitively understand whether experimental drugs are exerting their intended effects .
+ Currently , 16 therapeutics targeting the alpha-synuclein pathology are in human trials : nine in Phase I , six in Phase II and one in Phase III . The experimental therapies being studied are designed either to clear clumps of alpha-synuclein from the brain or to block the process that causes clumps to form .
+ The a-syn therapeutics in development employ a range of approaches , including vaccine- and monoclonal antibody-based immunotherapy and oral small molecule inhibitors . The most advanced programs from Prothena / Roche ( prasinezumab ) and Annovis Bio ( buntanetap ) should be reporting data from their ongoing trials in late 2023 or in 2024 .
Dopamine
This supercharged pipeline promises more effective therapies will be available sooner .
People with Parkinson ’ s can look forward to new options for treating their symptoms , with as many as five new drugs to increase dopamine levels potentially receiving U . S . Food and Drug Administration approval in the coming months . All feature delivery innovations to make them longer lasting and easier to take .
+ As of fall 2023 , two were in review with the FDA : Amneal ’ s IPX203 offers an oral extended-formulation of carbidopa and
18